Rafaat Rahmani, CEO of Lifescience Dynamics, discusses current trends in drugs approval and why a resurgence is being seen in provision for Alzheimer's Historically, market authorisations for...
Already-approved combination of medication could see clinical studies around life-saving potential move quickly
New inquiry from APPG on Dementia lays bare the regional disparities that exist in diagnosis and support
Deep learning framework can help maximise outcomes for those with mild cognitive impairment
Largest-ever clinical trial reveals symptoms disappeared in ten weeks for 56 per cent of participants
Trials of donanemab have shown its potential in slowing progress of early-stage Alzheimer's disease
Research in mice revealed intervention could lead to motor recovery seven days after stroke
International clinical trial finds chances of a recurrent event with earlier treatment are likely to be lower
Gene activity in blood vessels in the brain are potentially targetable with existing or future drugs to improve stroke recovery
Letter to Government argues move would better support patients and relieve pressure on NHS
